source
- Pfizer licenses three in vivo CAR-T assets from Starna for $330 million to target autoimmune disease outside Greater ChinaPfizer announced a licensing agreement with Starna Therapeutics, a Chinese biotech, to acquire exclusive rights to three pre-IND in vivo CAR-T programs aimed at autoimmune diseases. Under the deal…
- Big Pharma execs urge biotech firms to be transparent and patient to win dealsAt Fierce Biotech's London Life Sciences Week, representatives from five major pharmaceutical companies shared how they evaluate biotech partners. Bayer's head of business development warned that…